Skip to content

Efficacy Study of Acupoint Sticking in Summer to Treat Asthma

Efficacy Study of Acupoint Sticking in Treating Winter Diseases in Summer to Treat Asthma of Kidney Yang Deficiency Type

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02580942
Enrollment
72
Registered
2015-10-20
Start date
2015-07-31
Completion date
2017-09-30
Last updated
2017-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

The purpose of this study is to assess whether Acupoint Sticking in Treating Winter Diseases in Summer is effective in the treatment of chronic asthma.

Detailed description

Asthma is a common chronic disease with an estimated 300 million worldwide. Treating Winter Diseases in Summer of traditional Chinese medicine treatment of asthma has a long history. But there are less related clinical trials. The purpose of this study is to assess whether Acupoint Sticking in Treating Winter Diseases in Summer is effective in the treatment of chronic asthma. After screening period, participants will undergo a physical examination, lung function, blood and induced sputum collection while being randomly assigned to one of the following 2 groups for 6 weeks during summer dog days of treatment: Group A will receive acupoint sticking treatment of Chinese herbal medicine and magnetic stickers once every two days; Group B will receive acupoint sticking treatment of Chinese herbal medicine and sham magnetic stickers once every two days. Questionnaires to assess asthma control and quality of life will be completed. A physical examination, blood collection, and induced sputum collection will occur at selected visits.

Interventions

DEVICEMagnetic stickers

36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.

DEVICESham magnetic stickers

36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.

72 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22).

Sponsors

Shanghai Municipal Health Bureau
CollaboratorOTHER_GOV
Shanghai University of Traditional Chinese Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients diagnosed with mild-to-moderate remission phase of asthma * Patients who have given written informed consent

Exclusion criteria

* Participation in another clinical trial 1 month prior to study entry * Participation received acupoint sticking of winter disease cured in summer * Use of corticosteroids 4 weeks prior to study entry * Patients who are allergic to therapeutic medicine * Female patients in lactation period, pregnancy or planning to get pregnant during the trial * Patients with severe primary diseases such as cancer, cardiovascular system, digestive system, kidney and hematopoietic system diseases * Patients with mental illness, acrasia

Design outcomes

Primary

MeasureTime frame
Total score Change from Baseline of Asthma Control TestMeasured during the 6 week treatment period

Secondary

MeasureTime frame
Cytokine levels of serum and induced sputumMeasured during the 6 week treatment period
Lung function(FEV1, PVC, PEF)Measured during the 6 week treatment period

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026